Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 11, 1999, Pages 903-908

  Luo, Jian Dong ^a   Zhang, Wei Wen ^a   Zhang, Gui Ping ^a   Guan, Jin Xia ^a   Chen, Xiu ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Angiotensin converting enzyme activity; Angiotensin converting enzyme inhibitor; Cardiac hypertrophy; Simvastatin; Ventricular function

Indexed keywords

ANGIOTENSIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYPROLINE; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA STENOSIS; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE PERFORMANCE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; MALE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA, ABDOMINAL; BLOOD PRESSURE; CAPTOPRIL; HEMODYNAMIC PROCESSES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYDROXYPROLINE; HYPERTROPHY, LEFT VENTRICULAR; ORGAN SIZE; PEPTIDYL-DIPEPTIDASE A; RATS; SIMVASTATIN; TIME FACTORS;

EID: 0032745205     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.03165.x     Document Type: Article

References (20)

1. 1. Baker KM, Booz, GW, Dostal DE. Cardiac actions of angiotensin II. Role of an intracardiac renin-angiotensin system. Annu. Rev. Physiol. 1992; 54: 227-41.
2. 2. Lindpainter K, Ganten D. The cardiac renin-angiotensin system: An appraisal of present experimental and clinical evidence. Circ. Res. 1991; 68: 905-21.
3. 3. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin conversion enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: Effect on coronary resistance, contractility, and relaxation. J. Clin. Invest. 1990; 86: 1913-20.
4. 4. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 1992; 327: 685-91.
5. 5. Richer C, Mulder P, Fornes P, Domergue V, Heudes D, Guidicelli JF. Long-term treatment with trandolaprol opposed cardiac remodeling and prolongs survival after myocardial infarction on rats. J. Cardiovasc. Pharmacol. 1992; 20: 147-56.
6. 6. Baker KM, Cherin MI, Wixon SK, Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am. J. Physiol. 1990; 259: H324-32.
7. 7. Dahlof B, Pennert K, Hansson L. Regression of left ventricular hypertrophy: A meta-analysis. Clin. Exp. Hypertens. 1992; A14: 173-80.
8. 8. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
9. 9. Hahenicht AJR, Glomset JA, Ross R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J. Biol. Chem. 1980; 255: 5134-40.
10. 10. Raiteri M, Arnaboldi L, Mcgeady P et al. Pharmacological control of the mevalonate pathway: Effect on arterial smooth muscle cell proliferation. J. Pharmacol. Exp. Ther. 1997; 281: 1144-53.
11. 11. Mitani H, Bandoh T, Ishikawa J, Kimura M, Totsuka T, Hayashi S. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br. J. Pharmacol. 1996; 119: 1269-75.
12. 12. Weinberg EO, Schoen FJ, George D et al. Angiotensin-converting enzyme inhibition prolongs survival and modified the transition to heart failure in rats with pressure overload hypertophy due to ascending aortic stenosis. Circulation 1994; 90: 1410-22.
13. 13. Prockop DJ, Udenfriend S. A specific method for the analysis of hydroxyproline in tissues and urine. Anal. Biochem. 1960; 1: 228-39.
14. 14. Lieberman J. Elevation of serum angiotension-converting-enzyme (ACE) level in sarcoidosis. Am. J. Med. 1975; 59: 365-72.
15. 15. Lowry OH, Tosebrough NJ, Farr AL, Randall RJ. Protein measurements with the Folin phenol reagent. J. Biol. Chem. 1954; 7: 341-51.
16. 16. Flesch M, Schiffer F, Zolk O et al. Contractile systolic and diastolic dysfunction in renin-induced hypertensive cardiomyopathy. Hypertension 1997; 30: 383-91.
17. 17. Emanul RL, Cain JP, Willians GH. Double antibody radioimmunoassay of renin activity and angiotensin II in human peripheral plasma. J. Lab. Clin. Med. 1973; 81: 632-40.
18. 18. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
19. 19. Yamazaki T, Yazaki Y. Is there major involvement of the renin-angiotensin system in cardiac hypertrophy ? Circ. Res. 1997; 81: 639-42.
20. 1 receptor inhibition: Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. Circulation 1997; 95: 1592-600.